Somatropin - BresaGen

Drug Profile

Somatropin - BresaGen

Alternative Names: Human growth hormone - BresaGen

Latest Information Update: 28 May 2007

Price : $50

At a glance

  • Originator BresaGen
  • Class Growth hormones; Hormonal replacements
  • Mechanism of Action Somatotropin receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • Discontinued Somatotropin deficiency

Most Recent Events

  • 03 Feb 2004 The directors of BresaGen have resigned and administrators have been appointed
  • 03 Dec 2003 BresaGen plans to commercialise somatropin in collaboration with pharmaceutical partners
  • 11 Jul 2001 Preclinical development for Somatotropin deficiency in Australia (Unknown route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top